ORMP · Healthcare
Oramed Pharmaceuticals Inc
12/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
16
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$175M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About ORAMED PHARMACEUTICALS INC
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Who's behind the signal
Every informed buyer we can see on ORMP, across all three feeds.
Hedge funds · 3
Millennium Management (Englander)
New position
Point72 (Steve Cohen)
Increased +2%
Citadel Advisors
Decreased −50%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 3 on record
Disclosures from 2021-04-23 to 2022-01-14
The newest disclosure we hold for this stock is 2022-01-14.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-01-14 | Andrew R. Garbarino · R-NY | House | Sold | $1,001 - $15,000 |
| 2021-10-01 | Andrew R. Garbarino · R-NY | House | Sold | $1,001 - $15,000 |
| 2021-04-23 | Andrew R. Garbarino · R-NY | House | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
ORAMED PHARMACEUTICALS INC isn't in the top-10 model right now, but 3 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
3
Investors
1
New positions
1
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Millennium Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+2%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−50%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ORAMED PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ORAMED PHARMACEUTICALS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime